Companies · Pharmaceuticals

Tribute Pharmaceuticals Canada Inc.

Milton · Pharmaceuticals

Diligence memoA one-page analyst read on Tribute Pharmaceuticals Canada Inc. — recommendation, valuation, rhythm, risks.
$92.1M
Total raised · real
7
Rounds
1.0×
Latest step-up
Top 11%
Sector rank · raised
Series C
Latest stage · inferred · Fri Feb 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Tribute Pharmaceuticals Canada Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.13× the median modeled value of Series C Pharmaceuticals companies in 2016–2018 (32 peers) — value vs value, same stage and era.
  • Within the normal band (113% of peer median) for its niche.
Dormant
  • Last raise 10.4 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Tribute Pharmaceuticals Canada Inc. is one of 1613 Pharmaceuticals companies tracked from Milton. By capital raised it ranks among the largest (ahead of 90% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeries C · Raised $808K (real) Modeled valuation $3.5M (est)Series CSeries C · Raised $6.6M (real) Modeled valuation $29M (est)Series CSeries C · Raised $276K (real) Modeled valuation $1.2M (est)Series CSeries A · 2013-03-01 Raised $4.3M (real) Modeled valuation $132M (est)Series A2013Series A · 2014-10-01 Raised $1.1M (real) Modeled valuation $35M (est)Series A2014Series A · 2015-05-21 Raised $4.1M (real) Modeled valuation $127M (est)Series A2015Series C · 2016-02-05 Raised $75M (real) Modeled valuation $2.6B (est)Series C2016Series C · 2016-02-05 Raised $75M (real) Modeled valuation $2.6B (est)Series C2016+$6.6M+$276K+$4.3M+$1.1M+$4.1M+$75M+$75MCumulative $167M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series C$808K
Series C extension$6.6M
Series C extension$276K
Bridge · Series C-stage$4.3M · 2013smaller follow-on
Bridge · Series C-stage$1.1M · 2014smaller follow-on
Bridge · Series C-stage$4.1M · 2015smaller follow-on
Series C extension$75.0M · 2016
Series C extension$75.0M · 2016

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 40%.

Modeled valuation trajectory
$2.6B
Base estimate est.
$243.6M
Conservative case
$6.9B
Upside case
$500.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Series C · modeled $3.5M · Series C · modeled $28.7M · Series C · modeled $1.2M · Series A · modeled $132.3M · 2013-03-01Series A · modeled $34.6M · 2014-10-01Series A · modeled $126.9M · 2015-05-21Series C · modeled $2.6B · 2016-02-05Series C · modeled $2.6B · 2016-02-052016
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
66%
Survival probability
49% low · 76% high
1.42×/yr
Annual markup
1.62×/yr upside case
6.0 yr
Elapsed time used
10.4 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
79 mo
Avg between rounds
$2.0M/yr
Capital velocity
56.5 yr
On record since
1970
First round
8
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 11× above median
This company$92.1M
Sector median$8.1M
Latest round — vs other Series C rounds in sector (real $, this stage) 1.6× above median
This company$75.0M
Sector median$46.4M
Modeled value — vs sector median (estimate, all stages) 35× above median
This company$2.6B
Sector median$76.1M

Raised more than 90% of sector peers (real $). Modeled value above 96% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #8 of 32.

This companyCohort peer
$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Amplyx Pharmaceuticals, Inc. · Series C Raised $116.6M · modeled $3.2B (est)Ligand Pharmaceuticals Inc · Series C Raised $85.4M · modeled $3.0B (est)Homology Medicines, Inc. · Series C Raised $127.1M · modeled $2.9B (est)KSQ Therapeutics, Inc. · Series C Raised $80.6M · modeled $2.8B (est)TP Therapeutics, Inc. · Series C Raised $126.4M · modeled $2.8B (est)Milestone Pharmaceuticals Inc. · Series C Raised $91.3M · modeled $2.8B (est)Aprecia Pharmaceuticals Co · Series C Raised $175.4M · modeled $2.8B (est)Aralez Pharmaceuticals Inc. · Series C Raised $75.0M · modeled $2.6B (est)Daisy Pharma Opioid Venture, LLC · Series C Raised $75.0M · modeled $2.6B (est)Forty Seven, Inc. · Series C Raised $109.1M · modeled $2.6B (est)MEI Pharma, Inc. · Series C Raised $76.1M · modeled $2.6B (est)Tribute Pharmaceuticals Canada Inc. (this company) Raised $92.1M · modeled $2.6B (est)Tribute Pharmaceuticals Canada Inc.
CompanyStageRaised · realValue · estvs peer med.
Amplyx Pharmaceuticals, Inc.Series C$116.6M$3.2B1.38×
Ligand Pharmaceuticals IncSeries C$85.4M$3.0B1.29×
Homology Medicines, Inc.Series C$127.1M$2.9B1.26×
KSQ Therapeutics, Inc.Series C$80.6M$2.8B1.22×
TP Therapeutics, Inc.Series C$126.4M$2.8B1.21×
Milestone Pharmaceuticals Inc.Series C$91.3M$2.8B1.21×
Aprecia Pharmaceuticals CoSeries C$175.4M$2.8B1.19×
Tribute Pharmaceuticals Canada Inc. this companySeries C$92.1M$2.6B1.13×
Aralez Pharmaceuticals Inc.Series C$75.0M$2.6B1.13×
Daisy Pharma Opioid Venture, LLCSeries C$75.0M$2.6B1.13×
Forty Seven, Inc.Series C$109.1M$2.6B1.13×
MEI Pharma, Inc.Series C$76.1M$2.6B1.13×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$4.3M2013-03-01$19.4M$132.3M90%
Series A$1.1M2014-10-01$5.1M$34.6M90%
Series A$4.1M2015-05-21$18.6M$126.9M90%
Series C$75.0M2016-02-05$500.0M$2.6B90%
Series C$75.0M2016-02-05$500.0M$2.6B90%
Series C$808K$5.4M$3.5M90%
Series C$6.6M$43.9M$28.7M90%
Series C$276K$1.8M$1.2M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$4.3M2013-03-01
    • First recorded raise — entered as Series A.
  2. Series A$1.1M2014-10-01
    • Raised 19 mo later, in step with the ~13 mo sector norm.
    • Round 3.8× smaller than the prior — bridge or down round.
  3. Series A$4.1M2015-05-21
    • Came back fast: 8 mo vs the ~13 mo sector norm.
    • Round 3.7× larger than the prior — scaling up.
  4. Series C$75.0M2016-02-05
    • Raised 9 mo later, in step with the ~13 mo sector norm.
    • Round 18.3× larger than the prior — scaling up.
  5. Series C$75.0M2016-02-05
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
Intelligence
2022 ~Q3
Modeled next raise · ~79mo cadence
$75.0M
Modeled next size est.range $75.0M$120.0M
1.0×
Last step-up
$2.0M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Robert Harris8 other2013-03
Andrew I. Koven3 other2016-02
Eric L. Trachtenberg3 other2016-02
Robert L. Harris3 other2016-02
Robert M. Harris1 other2015-05
Scott J. Charles1 other2016-02
Steven H Goldman1 other2013-03
Arnold J. Tenney2014-10
Arnold S. Tenney2013-03
Bernard I. Chiasson2016-02
F. Martin Thrasher2013-03
Janice Martin Clarke2013-03
Janice M. Clarke2014-10
John J. Kime2014-10
John M. Gregory2013-03
John M. Kime2013-03
Murray I. Roach2016-02
Robert H. Gregory2014-10
Robert H. Harris2014-10
Scott J. Langille2014-10
Scott Martin Langille2013-03
Registry & provenance

Tribute Pharmaceuticals Canada Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1159019
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Aralez Pharmaceuticals Inc.PharmaceuticalsSeries C$75.0M$2.6Bnetwork3 shared operators · same sector · same stage
KALA BIO, Inc.BiotechnologySeries C$158.8M$8.3Mnetwork2 shared operators · same stage
Amarantus Bioscience Holdings, Inc.PharmaceuticalsSeed$6.0M$11.4Mnetwork2 shared operators · same sector
Sentia Wellness, Inc.PharmaceuticalsSeries C$91.6M$3.2Bsame sector · same stage
Milestone Pharmaceuticals Inc.PharmaceuticalsSeries C$91.3M$2.8Bsame sector · same stage
Paratek Pharmaceuticals IncPharmaceuticalsSeries C$93.0M$3.3Bsame sector · same stage
Aptinyx Inc.PharmaceuticalsSeries C$95.0M$2.5Bsame sector · same stage
Vytalyx IncPharmaceuticalsSeries C$88.4M$2.1Bsame sector · same stage
Frequently asked
How much funding has Tribute Pharmaceuticals Canada Inc. raised?
Tribute Pharmaceuticals Canada Inc. has raised approximately $92.1M in disclosed capital across 7 recorded financing rounds, aggregated from public filings.
What is Tribute Pharmaceuticals Canada Inc.'s estimated valuation?
Provath's modeled valuation for Tribute Pharmaceuticals Canada Inc. is approximately $2.6B (modeled range $243.6M–$6.9B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Tribute Pharmaceuticals Canada Inc. at?
Tribute Pharmaceuticals Canada Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Fri Feb 05.
What does Tribute Pharmaceuticals Canada Inc. do and where is it based?
Tribute Pharmaceuticals Canada Inc. operates in the Pharmaceuticals sector, based in Milton.
Explore related

See where Tribute Pharmaceuticals Canada Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Tribute Pharmaceuticals Canada Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.